Results of cost-effectiveness evaluation over 48-week analysis
| Outcome | TC | CM | Incremental (TC–CM) |
| Proportion of time in remission | 0.582 | 0.468 | 0.114 |
| Hospitalisation events per patient | 0.124 | 0.297 | −0.173 |
| Adalimumab injections, 40 mg | 31.01 | 24.74 | 6.27 |
| Direct medical costs | |||
| Adalimumab costs | £10 770 | £8601 | £2170 |
| CRP and FC testing costs | £109 | £0 | £109 |
| Hospitalisation costs | £1044 | £2506 | −£1462 |
| Other direct medical costs | £1332 | £1556 | −£224 |
| Total costs | £13 255 | £12 662 | £593 (95% CI: £−12 952 to £2096) |
| Total QALYs | 0.668 | 0.636 | 0.032 (95% CI: 0.011 to 0.055) |
| ICER (excluding absenteeism) | £18 656 | ||
| Incremental net monetary benefit (excluding absenteeism) | £360 | ||
| Change in absenteeism | −£3962 | −£2748 | −£1214 |
| ICER (including absenteeism) | TC dominant | ||
| Incremental net monetary benefit (including absenteeism) | £1575 |
CM, Clinical management strategy; CRP, C-reactive protein; FC, faecal calprotectin; ICER, incremental cost-effectiveness ratio.; QALY, quality-adjusted life-year; TC, tight control strategy.